Platelet Hyperreactivity to Aspirin and Stroke

PHASE4CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
StrokeCerebral InfarctionCardiovascular DiseasesVascular DiseasesAtherosclerosisIschemiaThrombosisAcute Coronary Syndrome
Interventions
DRUG

Aspirin (platelet sensitive versus platelet hyperreactivity)

"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."

Trial Locations (1)

05403000

University of Sao Paulo, School of Medicine, São Paulo

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

collaborator

Accumetrics, Inc.

INDUSTRY

collaborator

Helena Laboratories Point of Care

UNKNOWN

collaborator

Chrono-Log Corporation

UNKNOWN

lead

University of Sao Paulo

OTHER

NCT00766896 - Platelet Hyperreactivity to Aspirin and Stroke | Biotech Hunter | Biotech Hunter